[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microvascular-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microvascular-complications":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,84,115,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620603","non-invasive-microvascular-assessment-in-individuals-at-high-risk-of-cardiovascular-disease-from-the-scapis2-study-100620603",false,"NCT07359768","Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study","SCAPIS 2 - Spectrum Study -CVD Risk Based on Microvascular Dysfunction","Inclusion Criteria:\n\n* Participated in the SCAPIS baseline (SCAPIS 1 study, 10 years ago)\n* Cohort specific inclusion criteria apply, as stated in 'groups' section\n* Has been invited to SCAPIS 2 core Singed informed consent to SCAPIS 2 core\n\nExclusion Criteria:\n\n* Scarring, tattoos, or amputations that preclude device examination\n* Cohort specific exclusion criteria apply, as stated in 'groups' section","ALL",{"count":18,"type":19},900,"ESTIMATED","OBSERVATIONAL","Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis, stroke, dementia, and kidney failure. Chronic low-grade inflammation linked to metabolic syndrome may further drive systemic microvascular impairment. Early detection of these subclinical processes using non-invasive assessments could facilitate timely interventions to prevent disease progression.\n\nSCAPIS 2 Spectrum is a prospective observational sub-study of the Swedish Cardiopulmonary Bioimage Study (SCAPIS-2), recruiting approximately 900 subjects aged 60-75 years. The study is organized into five arms-obstructive coronary artery disease (O-CAD), angina with nonobstructive coronary arteries (ANOCA), metabolic syndrome with diabetes, left ventricular systolic dysfunction, and left ventricular diastolic dysfunction-each defined by specific inclusion and exclusion criteria. Participants will undergo a comprehensive microvascular assessment using investigational devices (including Perimed Periflux EPOS, PeriCam MultiFlow, and TCI P4) alongside stress cardiac magnetic resonance imaging (stress-CMR) for cardiac-specific evaluation.",[23,24],"Cardiovascular Diseases","Microvascular Complications",[26,27,28,29,30,31,32],"microvascular","non-invasive","microcirculation","spatial frequency domain imaging","cardiac magnetic resonance imaging","laser speckle contrast imaging","laser doppler flowmetry","RECRUITING","2026-01-13",{"date":36,"type":37},"2026-01-22","ACTUAL",{"date":39,"type":37},"2024-03-18",{"date":41,"type":19},"2026-12-29",{"name":43,"class":44},"HJN Sverige AB\u002FNeko Health","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":59,"conditions":60,"keywords":71,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100460586","brain-health-in-youth-with-normal-weight-overweight-and-obesity-at-risk-for-type-2-diabetes-t2d-100460586","NCT05277558","Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)","Brain Health Across the Metabolic Continuum in Youth at Risk for Type 2 Diabetes (T2D)","Metabrain","Inclusion Criteria:\n\n* 12-17 yrs. old at visit 1, 12-19 yrs. old at visit 2, Tanner II or above (determined through an exam by a pediatric endocrinologist or certified nurse practitioner trained in pediatric endocrinology), otherwise healthy except for obesity, \\\u003C450 lbs. (due to MRI scanner limits), able and willing to lie flat within the MRI scanner and do cognitive testing, fluent in English.\n\nExclusion Criteria:\n\n* Syndromic obesity, history of bariatric surgery, insulin treatment (metformin allowed if \\\u003C 6 months) for T2D, contraindications for MRI (metal, claustrophobia), braces, pregnant (pregnancy test will be done on post-menarchal girls) or breastfeeding, inability to participate in cognitive testing due to sensory or language issues, intellectual disability, special education, pharmacologic treatment for Attention Deficit Hyperactivity Disorder (ADHD), prematurity (\\\u003C36 weeks gestation), complications at birth, neurologic co-morbidities (e.g., seizures, stroke, head injury with \\>10 min loss of consciousness), significant psychiatric disorders (e.g., schizophrenia, bipolar disorder, current major depression), taking psychoactive medications (e.g., antipsychotics) that would interfere with testing or reporting illegal drug use. Self-reported smoking and alcohol use and length of time with obesity will be assessed by history (although these measures may not be fully reliable).",true,"12 Years","17 Years",{"count":58,"type":19},117,"Investigators propose to study youth across the spectrum of body mass index (BMI) and dysglycemia. This approach will allow investigators to disentangle the relationship of key features of type 2 diabetes (T2D) risk (e.g. obesity) with intermediary physiologic changes (e.g. insulin resistance, inflammation, β-cell dysfunction and dysglycemia) that pose a risk for the brain. Investigators will determine which of these factors are most associated with differences in brain structure and function among groups, over time, and how these effects differ from normal neurodevelopment.",[61,62,63,24,64,65,66,67,68,69,70],"Type2 Diabetes","Type 2 Diabetes Mellitus in Obese","Dysglycemia","Brain Structure","Obesity, Childhood","Diabetes in Adolescence","Inflammation","Insulin Resistance","Overweight, Childhood","Cognitive Decline",[72],"Brain, Health, Youth, Type 2 Diabetes Mellitus, overweight, obesity","2025-12-16",{"date":75,"type":37},"2025-12-18",{"date":77,"type":37},"2022-05-24",{"date":79,"type":19},"2027-10-31",{"name":81,"class":82},"Washington University School of Medicine","OTHER",2,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":54,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100604134","microangiopathy-in-diabetes-100604134","NCT07145567","Microangiopathy in Diabetes","Microangiopathy IN Diabetes","MIND","Inclusion Criteria:\n\n* Diabetes mellitus type 1.\n* Cohort specific inclusion criteria apply, please review 'groups' section.\n\nExclusion Criteria:\n\n* Patients unable to understand patient information due to cognitive impairment.\n* Patients unable to understand patient information due to language barriers.\n* Ongoing acute infection disease or inflammatory condition.\n* Pregnant or breast-feeding women.\n* Patients with damaged and\u002For scarred tissue in the areas of interest for the investigational or comparator devices.","18 Years","60 Years",{"count":95,"type":19},400,"This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.",[98,24],"Microangiopathy",[100,101,102,103,104,105],"Laser speckle contrast imaging","Spatial frequency domain imaging","Laser doppler flowmetry","Iontophoresis","Local thermal hyperemia","Post occlusive reactive hyperemia","2025-08-21",{"date":108,"type":37},"2025-08-28",{"date":110,"type":37},"2024-03-01",{"date":112,"type":19},"2027-12",{"name":114,"class":82},"Karolinska Institutet",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":54,"sex":16,"minAge":93,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":45},"100564061","test-of-reproducibility-of-15oh20-pet-assessment-of-brain-perfusion-100564061","NCT06624267","Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion","Small Vessel Disease of the Brain and Heart: a Perfusion PET Study of Training Effects","SVAT","Inclusion Criteria:\n\n* Age \\> 60 years\n* No diagnosis of T2D according to WHO\\'s criteria.\n* Speaks and understands Danish (required for reliable cognitive testing)\n* Able to provide informed and written consent\n\nExclusion Criteria:\n\n* Moderate to high intensity training \\>2 times\u002Fweek.\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.",{"count":124,"type":19},8,"In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.\n\nIt has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.\n\nAmong other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.\n\nExercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions.\n\nSystemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max).",[127,24,128,129,130],"Microvascular Disease","Diabetes Mellitus Type 2","Cerebral Hypoperfusion","Dementia",[132,133,134,135,136,137],"microvascular disease","microvascular complications of the heart","microvascular complications of the brain","microvascular disease patophysiology","diabetes type 2","dementia","NOT_YET_RECRUITING","2024-10-02",{"date":141,"type":37},"2024-10-04",{"date":143,"type":19},"2024-11",{"date":112,"type":19},{"name":146,"class":82},"University Hospital Bispebjerg and Frederiksberg",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":121,"eligibilityCriteria":153,"healthyVolunteers":54,"sex":16,"minAge":93,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":125,"conditions":156,"keywords":157,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":161,"locationsCount":45},"100564370","comparison-of-differencens-in-vo2-max-perfusion-of-the-heart-and-brain-and-cognitive-performance-between-patients-with-type-2-diabetes-and-healthy-age-matched-controls-100564370","NCT06628297","Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.","Small Vessel Disease of the Brain and Heart a PET Perfusion Study of Training Effects","Inclusion Criteria for the patients with type 2 diabetes:\n\nDiabetes type II diagnose with one of the following:\n\n* Duration over 5 years\n* Moderate microalbuminuria\n* Non-proliferative diabetic retinopathy\n\n  * Speaks and understands Danish (required for reliable cognitive testing)\n  * Able to provide informed and written consent\n\nExclusion Criteria or the patients with type 2 diabetes:\n\nModerate to high intensity training \\>1 times\u002Fweek.\n\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.\n\nInclusion Criteria for the healthy age-matched controls:\n\n* Age \\> 60 years\n* No diagnosis of T2D according to WHO\\'s criteria.\n* Speaks and understands Danish (required for reliable cognitive testing)\n* Able to provide informed and written consent\n\nExclusion Criteria for the healthy age-matched controls:\n\n* Moderate to high intensity training \\>2 times\u002Fweek.\n* Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \\<45%), asthma.\n* Previous stroke or significant neurological disease including cognitive dysfunction.\n* Ongoing depression.\n* Hypothyroidism\n* Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.",{"count":155,"type":19},72,[127,24,130,128,129],[132,133,134,136,137,135],{"date":141,"type":37},{"date":143,"type":19},{"date":112,"type":19},{"name":146,"class":82}]